ATTAIN-MAINTAIN Analysis
Switching from Injectables to Oral Orforglipron (52 Weeks)
Weight Trajectory & Dynamics (kg)
Clinical Implications & Analysis
Wegovy: Solid Maintenance
Participants essentially held on to their prior weight loss. The change was negligible (+0.9 kg), effectively acting as a solid "doorstop" for weight maintenance.
Zepbound: ~5.5% Regain
A gain of 5.0 kg on a baseline of 90.9 kg implies roughly a +5.5% weight increase over one year. The "door" slipped back open.
Why the "Win" is Questionable
The safety profile was reported as "consistent with Phase 3," meaning patients likely experienced standard GI adverse events (nausea, vomiting).
The Skeptical View: Patients switching from Zepbound regained significant weight while still dealing with the side effects of a GLP-1. This trade-off raises doubts about the net clinical benefit for this specific subgroup.
👀 View Mode